Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

NCT02607228 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castrate-Resistant Prostate Cancer

Interventions

DRUG: Alobresib
DRUG: Enzalutamide

Sponsor

Gilead Sciences